| 1 | LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC | 2.3 | 7 | Citations (PDF) |
| 2 | Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites | 6.8 | 60 | Citations (PDF) |
| 3 | Unification of Efforts to Improve Global Access to Cancer Therapeutics: Report From the 2022/2023 Access to Essential Cancer Medicines Stakeholder Summit | 2.1 | 9 | Citations (PDF) |
| 4 | A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study | 2.1 | 131 | Citations (PDF) |
| 5 | A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC | 0.9 | 13 | Citations (PDF) |
| 6 | Development and Validation of a Decision Analytical Model for Posttreatment Surveillance for Patients With Oropharyngeal Carcinoma | 6.6 | 11 | Citations (PDF) |
| 7 | Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer | 34.5 | 2,516 | Citations (PDF) |
| 8 | 2022 Presidential Address: Advancing Equitable Cancer Care Through Innovation | 16.9 | 1 | Citations (PDF) |
| 9 | Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma | 5.5 | 8 | Citations (PDF) |
| 10 | A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck | 6.8 | 21 | Citations (PDF) |
| 11 | Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives | 3.4 | 99 | Citations (PDF) |
| 12 | Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity | 12.5 | 73 | Citations (PDF) |
| 13 | A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101 | 2.4 | 17 | Citations (PDF) |
| 14 | Evaluation of Oncology Trial Results Reporting Over a 10-Year Period | 6.6 | 23 | Citations (PDF) |
| 15 | Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538 | 2.6 | 14 | Citations (PDF) |
| 16 | Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors | 6.8 | 41 | Citations (PDF) |
| 17 | Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC | 0.9 | 0 | Citations (PDF) |
| 18 | Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma | 6.8 | 73 | Citations (PDF) |
| 19 | Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer | 2.6 | 20 | Citations (PDF) |
| 20 | All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages | 13.4 | 54 | Citations (PDF) |
| 21 | CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer | 3.4 | 103 | Citations (PDF) |
| 22 | Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience | 2.4 | 30 | Citations (PDF) |
| 23 | Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901 | 2.8 | 43 | Citations (PDF) |
| 24 | Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol | 27.4 | 111 | Citations (PDF) |
| 25 | Adjuvant treatment for high‐risk salivary gland malignancies and prognostic stratification based on a 20‐year single institution experience | 1.6 | 4 | Citations (PDF) |
| 26 | A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab‐resistant head and neck cancer: The MAESTRO study | 4.0 | 18 | Citations (PDF) |
| 27 | Dose and Volume De-Escalation for Human Papillomavirus–Positive Oropharyngeal Cancer is Associated with Favorable Posttreatment Functional Outcomes | 1.5 | 20 | Citations (PDF) |
| 28 | A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma | 4.0 | 36 | Citations (PDF) |
| 29 | Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay | 2.1 | 37 | Citations (PDF) |
| 30 | Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use | 6.8 | 153 | Citations (PDF) |
| 31 | Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial | 4.0 | 96 | Citations (PDF) |
| 32 | Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer | 2.1 | 1 | Citations (PDF) |
| 33 | Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma | 5.4 | 36 | Citations (PDF) |
| 34 | A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited‐stage small cell lung cancer in elderly patients versus younger patients | 4.0 | 26 | Citations (PDF) |
| 35 | Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression | 2.4 | 757 | Citations (PDF) |
| 36 | Role of dental hardware in oral cavity squamous cell carcinoma in the low‐risk nonsmoker nondrinker population | 2.0 | 30 | Citations (PDF) |
| 37 | Feasibility of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Cytology Specimens for Next Generation Sequencing in Non–small-cell Lung Cancer | 2.8 | 79 | Citations (PDF) |
| 38 | Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC | 2.1 | 23 | Citations (PDF) |
| 39 | Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance) | 1.5 | 46 | Citations (PDF) |
| 40 | Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience | 2.4 | 51 | Citations (PDF) |
| 41 | The Impact of Staging by Positron-Emission Tomography on Overall Survival and Progression-Free Survival in Patients With Locally Advanced NSCLC | 2.1 | 13 | Citations (PDF) |
| 42 | Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor | 4.0 | 59 | Citations (PDF) |
| 43 | Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials | 3.4 | 12 | Citations (PDF) |
| 44 | Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck | 6.8 | 27 | Citations (PDF) |
| 45 | AHNS Series – Do you know your guidelines? Principles of treatment for nasopharyngeal cancer: A review of the National Comprehensive Cancer Network guidelines | 2.0 | 14 | Citations (PDF) |
| 46 | Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL | 3.4 | 20 | Citations (PDF) |
| 47 | Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial | 27.4 | 412 | Citations (PDF) |
| 48 | The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC | 2.1 | 225 | Citations (PDF) |
| 49 | Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer | 1.5 | 36 | Citations (PDF) |
| 50 | Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck | 34.5 | 4,947 | Citations (PDF) |
| 51 | Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE) | 2.1 | 11 | Citations (PDF) |
| 52 | Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer | 3.4 | 23 | Citations (PDF) |
| 53 | Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer | 34.5 | 8,144 | Citations (PDF) |
| 54 | ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non–Small Cell Lung Cancer | 6.8 | 116 | Citations (PDF) |
| 55 | HPV-Associated Head and Neck Cancer | 4.6 | 168 | Citations (PDF) |
| 56 | Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades | 9.9 | 14 | Citations (PDF) |
| 57 | Lung cancer—a fractal viewpoint | 70.7 | 190 | Citations (PDF) |
| 58 | Integrated Genomic Analysis Suggests
MLL3
Is a Novel Candidate Susceptibility Gene for Familial Nasopharyngeal Carcinoma | 1.1 | 19 | Citations (PDF) |
| 59 | Ex Vivo Antibody-Dependent Cellular Cytotoxicity Inducibility Predicts Efficacy of Cetuximab | 4.2 | 41 | Citations (PDF) |
| 60 | Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer | 34.5 | 9,057 | Citations (PDF) |
| 61 | Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups | 2.6 | 6 | Citations (PDF) |
| 62 | Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes | 6.8 | 350 | Citations (PDF) |
| 63 | Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma | 2.4 | 32 | Citations (PDF) |
| 64 | Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas | 6.8 | 623 | Citations (PDF) |
| 65 | Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer | 2.9 | 16 | Citations (PDF) |
| 66 | CALGB 30704 (Alliance): A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer | 2.1 | 51 | Citations (PDF) |
| 67 | Race and competing mortality in advanced head and neck cancer | 2.4 | 30 | Citations (PDF) |
| 68 | Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer | 2.9 | 3 | Citations (PDF) |
| 69 | Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer | 2.4 | 8 | Citations (PDF) |
| 70 | DNA Repair Biomarkers XPF and Phospho-MAPKAP Kinase 2 Correlate with Clinical Outcome in Advanced Head and Neck Cancer | 2.3 | 14 | Citations (PDF) |
| 71 | Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy | 1.8 | 38 | Citations (PDF) |
| 72 | Non–Small-Cell Lung Cancer: Then and Now | 16.9 | 29 | Citations (PDF) |
| 73 | New Radiotherapy and Chemoradiotherapy Approaches for Non–Small-Cell Lung Cancer | 16.9 | 77 | Citations (PDF) |
| 74 | Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70Gy daily radiotherapy: CALGB 30904 | 2.6 | 10 | Citations (PDF) |
| 75 | Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma | 2.4 | 11 | Citations (PDF) |
| 76 | Phase II Study of Induction Cisplatin and Irinotecan Followed by Concurrent Carboplatin, Etoposide, and Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer, CALGB 30206 | 2.1 | 24 | Citations (PDF) |
| 77 | A Pooled Analysis of Limited-Stage Small-Cell Lung Cancer Patients Treated with Induction Chemotherapy Followed by Concurrent Platinum-Based Chemotherapy and 70 Gy Daily Radiotherapy: CALGB 30904 | 2.1 | 51 | Citations (PDF) |
| 78 | Oral Chemotherapy in Head and Neck Cancer | 11.4 | 6 | Citations (PDF) |
| 79 | Cyclooxygenase-2 (COX-2) As a Predictive Marker for the Use of COX-2 Inhibitors in Advanced Non–Small-Cell Lung Cancer | 16.9 | 35 | Citations (PDF) |
| 80 | A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | 6.8 | 114 | Citations (PDF) |
| 81 | CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB 150304 | 2.1 | 60 | Citations (PDF) |
| 82 | Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer | 2.8 | 20 | Citations (PDF) |
| 83 | Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy | 2.4 | 13 | Citations (PDF) |
| 84 | Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107) | 2.6 | 68 | Citations (PDF) |
| 85 | Targeted and Cytotoxic Therapy in Coordinated Sequence (TACTICS): Erlotinib, Bevacizumab, and Standard Chemotherapy for Non–Small-Cell Lung Cancer, A Phase II Trial | 2.8 | 10 | Citations (PDF) |
| 86 | A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531 | 2.6 | 2 | Citations (PDF) |
| 87 | Pulmonary Toxicity in Stage III Non-Small Cell Lung Cancer Patients Treated With High-Dose (74 Gy) 3-Dimensional Conformal Thoracic Radiotherapy and Concurrent Chemotherapy Following Induction Chemotherapy: A Secondary Analysis of Cancer and Leukemia Group B (CALGB) Trial 30105 | 1.5 | 34 | Citations (PDF) |
| 88 | MET and Phosphorylated MET as Potential Biomarkers in Lung Cancer | 2.8 | 28 | Citations (PDF) |
| 89 | Concurrent Chemotherapy and Intensity-Modulated Radiotherapy for Organ Preservation of Locoregionally Advanced Oral Cavity Cancer | 1.3 | 32 | Citations (PDF) |
| 90 | Serum Vascular Endothelial Growth Factor and COX-2/5-LOX Inhibition in Advanced Non-small Cell Lung Cancer: Cancer and Leukemia Group B 150304 | 2.1 | 11 | Citations (PDF) |
| 91 | Personalized Treatment of Lung Cancer | 1.9 | 39 | Citations (PDF) |
| 92 | Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies | 1.8 | 43 | Citations (PDF) |
| 93 | A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers | 9.9 | 59 | Citations (PDF) |
| 94 | Crizotinib: ALK/Met inhibitor, oncolytic | 0.1 | 15 | Citations (PDF) |
| 95 | Prognostic Significance of Mucin and p53 Expression in Stage IB Non-small Cell Lung Cancer: A Laboratory Companion Study to CALGB 9633 | 2.1 | 24 | Citations (PDF) |
| 96 | Factors Associated With Long-term Speech and Swallowing Outcomes After Chemoradiotherapy for Locoregionally Advanced Head and Neck Cancer | 1.8 | 21 | Citations (PDF) |
| 97 | Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304) | 2.1 | 76 | Citations (PDF) |
| 98 | A Phase II Study of Dasatinib in Patients with Chemosensitive Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30602) | 2.1 | 50 | Citations (PDF) |
| 99 | Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia Group B (CALEB) 30106, a CALGB-Stratified Phase II Trial | 2.1 | 147 | Citations (PDF) |
| 100 | Phase II Study of Cediranib (AZD 2171), an Inhibitor of the Vascular Endothelial Growth Factor Receptor, for Second-Line Therapy of Small Cell Lung Cancer (National Cancer Institute #7097) | 2.1 | 77 | Citations (PDF) |
| 101 | A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia | 3.0 | 96 | Citations (PDF) |
| 102 | Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue | 2.0 | 21 | Citations (PDF) |
| 103 | Induction Chemotherapy for Head and Neck Cancer: Recent Data | 3.4 | 44 | Citations (PDF) |
| 104 | Chemoreirradiation for recurrent salivary gland malignancies | 2.0 | 34 | Citations (PDF) |
| 105 | Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer | 2.0 | 10 | Citations (PDF) |
| 106 | Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction | 2.3 | 12 | Citations (PDF) |
| 107 | Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium | 2.5 | 96 | Citations (PDF) |
| 108 | The Role of EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer | 3.4 | 61 | Citations (PDF) |
| 109 | Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck | 2.4 | 44 | Citations (PDF) |
| 110 | Induction Chemotherapy: To Use or Not to Use? That Is the Question | 2.7 | 21 | Citations (PDF) |
| 111 | PROCLAIM: A Phase III Study of Pemetrexed, Cisplatin, and Radiation Therapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiation Therapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Locally Advanced Stage III Non–Small-Cell Lung Cancer of Other than Predominantly Squamous Cell Histology | 2.8 | 50 | Citations (PDF) |
| 112 | Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy | 2.0 | 63 | Citations (PDF) |
| 113 | A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104 | 2.1 | 11 | Citations (PDF) |
| 114 | Neck Dissection Planning Based on Postchemoradiation Computed Tomography in Patients With Head and Neck Cancer | 1.8 | 1 | Citations (PDF) |
| 115 | Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801: Induction Chemotherapy Followed by Chemoradiotherapy Compared with Chemoradiotherapy Alone for Unresectable Stage III Non-small Cell Lung Cancer | 2.1 | 41 | Citations (PDF) |
| 116 | Neck Response to Chemoradiotherapy | 1.8 | 14 | Citations (PDF) |
| 117 | Phase II study of sunitinib malate in head and neck squamous cell carcinoma | 2.5 | 85 | Citations (PDF) |
| 118 | The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium | 2.5 | 6 | Citations (PDF) |
| 119 | Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia | 3.0 | 155 | Citations (PDF) |
| 120 | Expanding Role of the Medical Oncologist in the Management of Head and Neck Cancer | 251.3 | 106 | Citations (PDF) |
| 121 | Cooperative Group Portfolio in Locally Advanced Non–Small-Cell Lung Cancer: Are We Making Progress? | 2.8 | 7 | Citations (PDF) |
| 122 | Concurrent Chemotherapy and Re-irradiation for Locoregionally Recurrent Head and Neck Cancer | 1.9 | 48 | Citations (PDF) |
| 123 | Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: Analysis of CALGB phase III trial 9235 | 2.6 | 11 | Citations (PDF) |
| 124 | Cooperative Group Research Efforts in Lung Cancer: Focus on Early-Stage Non–Small-Cell Lung Cancer | 2.8 | 7 | Citations (PDF) |
| 125 | Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma | 9.9 | 45 | Citations (PDF) |
| 126 | Characteristics Associated With Swallowing Changes After Concurrent Chemotherapy and Radiotherapy in Patients With Head and Neck Cancer | 1.8 | 60 | Citations (PDF) |
| 127 | Randomized Phase II Study of Carboplatin and Etoposide With or Without thebcl-2Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103 | 16.9 | 166 | Citations (PDF) |
| 128 | Randomized Phase II Trial of Induction Chemotherapy Followed by Concurrent Chemotherapy and Dose-Escalated Thoracic Conformal Radiotherapy (74 Gy) in Stage III Non–Small-Cell Lung Cancer: CALGB 30105 | 16.9 | 180 | Citations (PDF) |
| 129 | Phase I Study of Bevacizumab Added to Fluorouracil- and Hydroxyurea-Based Concomitant Chemoradiotherapy for Poor-Prognosis Head and Neck Cancer | 16.9 | 154 | Citations (PDF) |
| 130 | Response to the Methylation Inhibitor Dihydro-5-azacytidine in Mesothelioma Is Not Associated with Methylation of p16INK4a: Results of Cancer and Leukemia Group B 159904 | 2.1 | 14 | Citations (PDF) |
| 131 | Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 | 2.1 | 2 | Citations (PDF) |
| 132 | Phase II Randomized Study of Dose-Dense Docetaxel and Cisplatin Every 2 Weeks With Pegfilgrastim and Darbepoetin Alfa With and Without the Chemoprotector BNP7787 in Patients With Advanced Non-small Cell Lung Cancer (CALGB 30303) | 2.1 | 15 | Citations (PDF) |
| 133 | Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 | 2.1 | 20 | Citations (PDF) |
| 134 | Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-small Cell Lung Cancer | 2.1 | 7 | Citations (PDF) |
| 135 | Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer | 2.1 | 66 | Citations (PDF) |
| 136 | Arsenic Trioxide in Patients With Adenocarcinoma of the Pancreas Refractory to Gemcitabine | 1.3 | 44 | Citations (PDF) |
| 137 | Free-Flap Reconstruction in the Doubly Irradiated Patient Population | 1.9 | 31 | Citations (PDF) |
| 138 | Locally Advanced Non-small Cell Lung Cancer: The Past, Present, and Future | 2.1 | 76 | Citations (PDF) |
| 139 | Induction Chemotherapy Followed by Chemoradiotherapy Compared With Chemoradiotherapy Alone for Regionally Advanced Unresectable Stage III Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B | 16.9 | 471 | Citations (PDF) |
| 140 | Chemoradiotherapy for Locally Advanced Head and Neck Cancer | 16.9 | 81 | Citations (PDF) |
| 141 | A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma | 4.1 | 23 | Citations (PDF) |
| 142 | The concurrent chemoradiation paradigm—general principles | 6.6 | 402 | Citations (PDF) |
| 143 | Aspiration in Chemoradiated Patients With Head and Neck Cancer | 1.8 | 99 | Citations (PDF) |
| 144 | Phase II Trial of Paclitaxel–Topotecan–Etoposide Followed by Consolidation Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer: CALGB 30002 | 2.1 | 39 | Citations (PDF) |
| 145 | Docetaxel and Exisulind in Previously Treated Non-small Cell Lung Cancer (NSCLC) Patients: A Multicenter, Phase II Clinical Trial | 2.1 | 6 | Citations (PDF) |
| 146 | The chemoradiation paradigm in head and neck cancer | 6.6 | 201 | Citations (PDF) |
| 147 | A Phase I Trial of Docetaxel Based Induction and Concomitant Chemotherapy in Patients with Locally Advanced Head and Neck Cancer | 1.6 | 11 | Citations (PDF) |
| 148 | Effects of radiotherapy with or without chemotherapy on tongue strength and swallowing in patients with oral cancer | 2.0 | 100 | Citations (PDF) |
| 149 | Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer | 1.5 | 39 | Citations (PDF) |
| 150 | The 2007 Inaugural ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer Symposium | 1.5 | 0 | Citations (PDF) |
| 151 | A Phase III Study of Surgical Resection and Paclitaxel/Carboplatin Chemotherapy with or Without Adjuvant Radiation Therapy for Resected Stage III Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B 9734 | 2.8 | 46 | Citations (PDF) |
| 152 | Key Signaling Pathways and Targets in Lung Cancer Therapy | 2.8 | 12 | Citations (PDF) |
| 153 | A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores | 2.1 | 30 | Citations (PDF) |
| 154 | Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers | 3.8 | 19 | Citations (PDF) |
| 155 | Reply to the Letter by Robins et al. | 2.1 | 0 | Citations (PDF) |
| 156 | Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions | 3.8 | 5 | Citations (PDF) |
| 157 | Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma | 1.5 | 241 | Citations (PDF) |
| 158 | A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma | 2.5 | 16 | Citations (PDF) |
| 159 | A phase II trial of O 6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma | 2.1 | 36 | Citations (PDF) |
| 160 | Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation | 2.0 | 155 | Citations (PDF) |
| 161 | Similar Outcomes Between African American and Non–African American Patients With Extensive-Stage Small-Cell Lung Carcinoma: Report From the Cancer and Leukemia Group B | 16.9 | 43 | Citations (PDF) |
| 162 | Reply to the Letter by Robins et al. | 2.1 | 6 | Citations (PDF) |
| 163 | Phase I/II Trial of Gefitinib and Oxaliplatin in Patients With Advanced Colorectal Cancer | 1.3 | 34 | Citations (PDF) |
| 164 | Phase I Study of Concomitant Chemoradiotherapy with Irinotecan, 5-FU., and Hydroxyurea for Patients with Advanced and/or Recurrent Head and Neck Cancer | 1.8 | 10 | Citations (PDF) |
| 165 | Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy | 1.5 | 47 | Citations (PDF) |
| 166 | Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer | 2.1 | 18 | Citations (PDF) |
| 167 | Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers | 2.5 | 65 | Citations (PDF) |
| 168 | Current treatments and promising investigations in a multidisciplinary setting | 9.9 | 11 | Citations (PDF) |
| 169 | Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732 | 16.9 | 181 | Citations (PDF) |
| 170 | Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck | 16.9 | 394 | Citations (PDF) |
| 171 | Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study | 16.9 | 275 | Citations (PDF) |
| 172 | Induction Paclitaxel/Carboplatin Followed by Concurrent Chemoradiation Therapy for Unresectable Stage III Non–Small-Cell Lung Cancer: A Limited-Access Study (CALGB 9534) | 2.8 | 32 | Citations (PDF) |
| 173 | Phase II Trial of PS-341 in Patients With Renal Cell Cancer: A University of Chicago Phase II Consortium Study | 16.9 | 145 | Citations (PDF) |
| 174 | A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer | 9.9 | 42 | Citations (PDF) |
| 175 | Phase I Study of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Carboplatin and Etoposide in Patients With Small-Cell Lung Cancer | 16.9 | 174 | Citations (PDF) |
| 176 | Analysis of further disease progression in metastatic non-small cell lung cancer: Implications for locoregional treatment | 3.8 | 44 | Citations (PDF) |
| 177 | Cetuximab in cancers of the lung and head & neck | 1.9 | 25 | Citations (PDF) |
| 178 | Concurrent chemoradiotherapy for head and neck cancer | 1.9 | 18 | Citations (PDF) |
| 179 | 9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium | 2.5 | 8 | Citations (PDF) |
| 180 | Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer | 2.0 | 131 | Citations (PDF) |
| 181 | Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck | 16.9 | 779 | Citations (PDF) |
| 182 | The Expanding Role of Systemic Therapy in Head and Neck Cancer | 16.9 | 203 | Citations (PDF) |
| 183 | Induction chemotherapy and radiotherapy in locally advanced non–small cell lung cancer | 2.2 | 6 | Citations (PDF) |
| 184 | Swallowing dysfunction—preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: A critical review | 1.5 | 204 | Citations (PDF) |
| 185 | A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer | 2.6 | 41 | Citations (PDF) |
| 186 | Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | 16.9 | 574 | Citations (PDF) |
| 187 | Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary | 9.9 | 52 | Citations (PDF) |
| 188 | Is Patient Travel Distance Associated With Survival on Phase II Clinical Trials in Oncology? | 4.6 | 145 | Citations (PDF) |
| 189 | Intensive Concurrent Chemoradiotherapy for Head and Neck Cancer with 5‐Fluorouracil‐ and Hydroxyurea‐Based Regimens: Reversing a Pattern of Failure | 3.4 | 45 | Citations (PDF) |
| 190 | Weekly Carboplatin and Paclitaxel Followed by Concomitant Paclitaxel, Fluorouracil, and Hydroxyurea Chemoradiotherapy: Curative and Organ-Preserving Therapy for Advanced Head and Neck Cancer | 16.9 | 217 | Citations (PDF) |
| 191 | An Attenuated Adenovirus, ONYX-015, As Mouthwash Therapy for Premalignant Oral Dysplasia | 16.9 | 141 | Citations (PDF) |
| 192 | A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain | 9.9 | 38 | Citations (PDF) |
| 193 | Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer | 9.9 | 80 | Citations (PDF) |
| 194 | A pilot trial of G3139, a bcl-2 antisense oligonucleotide,and paclitaxel in patients with chemorefractory small-cell lung cancer | 9.9 | 151 | Citations (PDF) |
| 195 | Phase I Study of Dose-Dense Alternating Doublets in Advanced Non—Small-Cell Lung Cancer | 2.8 | 2 | Citations (PDF) |
| 196 | Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study | 2.6 | 16 | Citations (PDF) |
| 197 | A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer | 2.1 | 13 | Citations (PDF) |
| 198 | Trends and perspectives in multimodality therapy of locoregionally advanced non-small cell lung cancer | 2.6 | 1 | Citations (PDF) |
| 199 | Chemotherapy in the management of squamous-cell carcinoma of the head and neck | 27.4 | 49 | Citations (PDF) |
| 200 | Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancer | 9.9 | 28 | Citations (PDF) |
| 201 | Concomitant Infusional Paclitaxel and Fluorouracil, Oral Hydroxyurea, and Hyperfractionated Radiation for Locally Advanced Squamous Head and Neck Cancer | 16.9 | 148 | Citations (PDF) |
| 202 | Locally advanced head and neck cancer | 3.9 | 18 | Citations (PDF) |
| 203 | Locally advanced non-small cell lung cancer | 3.9 | 0 | Citations (PDF) |
| 204 | Title is missing! | 2.5 | 28 | Citations (PDF) |
| 205 | Title is missing! | 2.5 | 20 | Citations (PDF) |
| 206 | Title is missing! | 2.5 | 20 | Citations (PDF) |
| 207 | Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer | 1.9 | 2 | Citations (PDF) |
| 208 | Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer | 1.9 | 7 | Citations (PDF) |
| 209 | Treatment of head and neck and esophageal xenografts employing Alimta and concurrent ionizing radiation | 3.8 | 7 | Citations (PDF) |
| 210 | Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non[ndash ]small cell lung cancer | 1.9 | 1 | Citations (PDF) |
| 211 | Induction Chemotherapy Followed by Concomitant Chemoradiotherapy for Non-Small Cell Lung Cancer | 3.4 | 0 | Citations (PDF) |
| 212 | A Phase I Study of STEALTH® Cisplatin (SPI-77) and Vinorelbine in Patients with Advanced Non–Small-Cell Lung Cancer | 2.8 | 16 | Citations (PDF) |
| 213 | Title is missing! | 2.5 | 2 | Citations (PDF) |
| 214 | Title is missing! | 2.5 | 11 | Citations (PDF) |
| 215 | A phase I–II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer | 9.9 | 36 | Citations (PDF) |
| 216 | The Role of Cervical Lymphadenectomy After Aggressive Concomitant Chemoradiotherapy | 1.8 | 182 | Citations (PDF) |
| 217 | Sex-associated differences in survival of patients undergoing resection for lung cancer | 2.3 | 131 | Citations (PDF) |
| 218 | Lung cancer | 62.1 | 627 | Citations (PDF) |
| 219 | Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532 | 2.6 | 25 | Citations (PDF) |
| 220 | Radiation Therapy With Concomitant Hydroxyurea and Fluorouracil in Stage II and III Head and Neck Cancer | 16.9 | 28 | Citations (PDF) |
| 221 | Volumetric visualization of head and neck CT data for treatment planning | 1.5 | 25 | Citations (PDF) |
| 222 | Title is missing! | 2.5 | 33 | Citations (PDF) |
| 223 | A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days | 2.1 | 17 | Citations (PDF) |
| 224 | A Phase II Trial of Oral Trimethylcolchicinic Acid in Patients with Hormone Refractory Prostate Cancer | 0.0 | 1 | Citations (PDF) |
| 225 | Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck 1999, 85, 164-170 | | 115 | Citations (PDF) |
| 226 | A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors | 4.0 | 4 | Citations (PDF) |
| 227 | Quality of Life and Performance in Advanced Head and Neck Cancer Patients on Concomitant Chemoradiotherapy: A Prospective Examination | 16.9 | 230 | Citations (PDF) |
| 228 | Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer | 2.5 | 29 | Citations (PDF) |
| 229 | Title is missing! | 2.5 | 16 | Citations (PDF) |
| 230 | Multimodality therapy in advanced paranasal sinus carcinoma: Superior long-term results | 1.5 | 5 | Citations (PDF) |
| 231 | Clinical Studies in Non-small Cell Lung Cancer: The CALGB Experience | 1.6 | 14 | Citations (PDF) |
| 232 | Enhancing the therapeutic index of concomitant chemoradiotherapy for head and neck cancer | 9.9 | 8 | Citations (PDF) |
| 233 | A phase I–II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer | 9.9 | 9 | Citations (PDF) |
| 234 | Induction chemotherapy, surgery, and concomitant chemoradiotherapy for carcinoma of the esophagus: A long-term analysis | 9.9 | 14 | Citations (PDF) |
| 235 | A Phase II Trial of Vinorelbine in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | 1.3 | 20 | Citations (PDF) |
| 236 | Osteoradionecrosis of the jaws as a risk factor in radiotherapy: a report of an eight-year retrospective review. | 2.8 | 12 | Citations (PDF) |
| 237 | Human Papillomavirus Expression and p53 Gene Mutations in Squamous Cell Carcinoma | 1.8 | 49 | Citations (PDF) |
| 238 | Thymidylate Synthase Expression and Response to Neoadjuvant Chemotherapy in Patients With Advanced Head and Neck Cancer | 4.6 | 63 | Citations (PDF) |
| 239 | Sexual Functioning and Head and Neck Cancer | 1.9 | 10 | Citations (PDF) |
| 240 | Does chemotherapy for head and neck cancer improve symptoms? | 9.9 | 0 | Citations (PDF) |
| 241 | Therapy for locoregionally advanced head and neck cancer | 2.7 | 8 | Citations (PDF) |
| 242 | Title is missing! | 2.1 | 81 | Citations (PDF) |
| 243 | Evaluation of neuropathy in patients on suramin treatment | 2.2 | 28 | Citations (PDF) |
| 244 | Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck | 4.0 | 22 | Citations (PDF) |
| 245 | Title is missing! | 2.5 | 6 | Citations (PDF) |
| 246 | Concomitant 5-FU, hydroxyurea and cisplatin with external beam radiation therapy for locally advanced pancreatic cancer | 2.8 | 1 | Citations (PDF) |
| 247 | Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: A potentially curable disease | 9.9 | 131 | Citations (PDF) |
| 248 | Ifosfamide plus paclitaxel in advanced non-small-cell lung cancer: A phase I study | 9.9 | 17 | Citations (PDF) |
| 249 | Chemotherapy for squamous cell carcinoma of head and neck: The future is now | 9.9 | 69 | Citations (PDF) |
| 250 | Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus | 2.1 | 5 | Citations (PDF) |
| 251 | Phase I study of treatment with oral 13- cis -retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin | 2.1 | 6 | Citations (PDF) |
| 252 | The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy-head and neck scale: A study of utility and validity | 4.0 | 584 | Citations (PDF) |
| 253 | Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support 1996, 77, 2308-2312 | | 4 | Citations (PDF) |
| 254 | Mineralocorticoid insufficiency due to suramin therapy 1996, 78, 2411-2420 | | 25 | Citations (PDF) |
| 255 | 88 Results of aggressive reirradiation with concomitant chemotherapy in recurrent unresectable head and neck cancer (HNC) | 1.5 | 0 | Citations (PDF) |
| 256 | 2117 Organ preservation in stage II and III head and neck cancer utilizing alternate week concomitant chemoradiotherapy | 1.5 | 0 | Citations (PDF) |
| 257 | Anaplastic carcinoma of the thyroid | 9.9 | 17 | Citations (PDF) |
| 258 | How I do it: Head and neck and plastic surgery: Surgical management of the head and neck cancer patient following concomitant multimodality therapy | 1.4 | 30 | Citations (PDF) |
| 259 | Phase II study of amonafide in the treatment of patients with advanced squamous cell carcinoma of the head and the neck | 2.5 | 3 | Citations (PDF) |
| 260 | Interferons and other cytokines in head and neck cancer | 2.3 | 8 | Citations (PDF) |
| 261 | Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction | 2.3 | 14 | Citations (PDF) |
| 262 | A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest | 2.1 | 9 | Citations (PDF) |
| 263 | Concomitant Chemoradiotherapy, Neutron Boost, and Adjuvant Chemotherapy for Anaplastic Astrocytoma and Glioblastoma Multiforme | 1.6 | 11 | Citations (PDF) |
| 264 | SWALLOWING FUNCTION FOLLOWING MULTISPECIALTY ORGAN PRESERVATION TREATMENT OF ADVANCED HEAD AND NECK-CANCER | 2.8 | 10 | Citations (PDF) |
| 265 | A phase I study of intermittent infusion cladribine in patients with solid tumors | 4.0 | 33 | Citations (PDF) |
| 266 | Time-dose relationship for local tumor control following alternate week concomitant radiation and chemotherapy of advanced head and neck cancer | 1.5 | 28 | Citations (PDF) |
| 267 | Chemotherapy, biologies, and chemoprevention as systemic therapies for head and neck cancer | 2.1 | 3 | Citations (PDF) |
| 268 | A PHASE-II TRIAL OF NEOADJUVANT CHEMOTHERAPY AND CONCOMITANT CHEMORADIOTHERAPY FOR THE TREATMENT OF LOCALLY ADVANCED NONSMALL CELL LUNG-CANCER | 2.8 | 0 | Citations (PDF) |
| 269 | Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study | 2.1 | 2 | Citations (PDF) |
| 270 | Escalating doses of interferon alpha-2A with cisplatin and concomitant radiotherapy: a phase I study | 2.1 | 11 | Citations (PDF) |
| 271 | Head and Neck Cancer | 34.5 | 1,724 | Citations (PDF) |
| 272 | Long-term experience with cisplatin-based induction chemotherapy and concomitant chemoradiotherapy in locally advanced head and neck cancer (HNC) | 4.9 | 2 | Citations (PDF) |
| 273 | Locoregionally Advanced Paranasal Sinus Carcinoma: Favorable Survival With Multimodality Therapy | 1.8 | 55 | Citations (PDF) |
| 274 | 5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: A clinical and pharmacologic analysis | 9.9 | 5 | Citations (PDF) |
| 275 | Chemotherapy and combined modality therapy in head and neck cancer | 2.1 | 3 | Citations (PDF) |
| 276 | Favorable Long-Term Survival Following Induction Chemotherapy With Cisplatin, Fluorouracil, and Leucovorin and Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Cancer | 4.6 | 99 | Citations (PDF) |
| 277 | Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: A feasible and active approach | 9.9 | 19 | Citations (PDF) |
| 278 | Chemotherapy in head and neck cancer | 2.1 | 8 | Citations (PDF) |
| 279 | Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: A randomized phase II study of the cancer and leukemia group B | 9.9 | 14 | Citations (PDF) |
| 280 | Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer | 2.1 | 7 | Citations (PDF) |
| 281 | 5-fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study | 2.1 | 22 | Citations (PDF) |
| 282 | Mutations of the p53 tumor suppressor gene may predict radiotherapy failure in head and neck cancer patients | 1.5 | 12 | Citations (PDF) |
| 283 | Concomitant Chemoradiotherapy With Cisplatin, 5-Fluorouracil and Hydroxyurea in Poor-Prognosis Head and Neck Cancer | 1.4 | 25 | Citations (PDF) |
| 284 | A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients | 0.7 | 5 | Citations (PDF) |
| 285 | Recent Advances in Radiation Therapy for Head and Neck Cancer | 2.2 | 6 | Citations (PDF) |
| 286 | Prognostic factors in advanced head and neck cancer patients undergoing multimodality therapy | 2.3 | 79 | Citations (PDF) |
| 287 | Chemotherapeutic and biologic radiation enhancement | 2.1 | 7 | Citations (PDF) |
| 288 | Survival and Analysis of Failure Following Hydroxyurea, 5-Fluorouracil and Concomitant Radiation Therapy in Poor Prognosis Head and Neck Cancer | 1.3 | 35 | Citations (PDF) |
| 289 | Chemotherapy and integrated treatment approaches in head and neck cancer | 2.1 | 3 | Citations (PDF) |
| 290 | A phase II study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer | 4.0 | 19 | Citations (PDF) |
| 291 | Serum immunoerythropoietin levels in patients with cancer receiving cisplatin-based chemotherapy | 4.0 | 32 | Citations (PDF) |
| 292 | Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study | 2.1 | 8 | Citations (PDF) |
| 293 | Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis | 2.1 | 10 | Citations (PDF) |
| 294 | Radiotherapy with Concomitant Chemotherapy for Head and Neck Cancer | 2.2 | 18 | Citations (PDF) |
| 295 | Review: 5-Fluorouracil cardiotoxicity: A critical review | 9.9 | 108 | Citations (PDF) |
| 296 | A randomised study comparing intermittent to continuous administration of magnesium aspartate hydrochloride in cisplatin-induced hypomagnesaemia | 5.5 | 18 | Citations (PDF) |
| 297 | Phase ii trial of etoposide and doxorubicin in advanced head and neck cancer | 0.0 | 2 | Citations (PDF) |
| 298 | A randomized study comparing two regimens of neoadjuvant and adjuvant chemotherapy in multimodal therapy for locally advanced head and neck cancer | 4.0 | 34 | Citations (PDF) |
| 299 | 5-Fluorouracil With Oral Leucovorin and Hydroxyurea and Concomitant Radiotherapy for Stage III Non-Small Cell Lung Cancer | 4.0 | 18 | Citations (PDF) |
| 300 | Chemotherapy-related hemolytic-uremic syndrome after the treatment of head and neck cancer. A case report | 4.0 | 19 | Citations (PDF) |
| 301 | Role of systemic therapy in advanced non-small-cell lung cancer | 2.0 | 13 | Citations (PDF) |
| 302 | A Randomized Study of Inpatient versus Outpatient Continuous Intravenous Infusion Chemotherapy: Psychosocial Aspects | 0.4 | 14 | Citations (PDF) |
| 303 | Heat Shock Proteins in Normal and Leukemic Blood Cells | 1.5 | 5 | Citations (PDF) |
| 304 | Radioresistant tumor cell lines derived from head and neck radiation failures | 2.0 | 6 | Citations (PDF) |
| 305 | Epidermal growth factor receptor gene amplification and expression in head and neck cancer cell lines | 2.0 | 79 | Citations (PDF) |
| 306 | A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer | 4.0 | 43 | Citations (PDF) |
| 307 | Clinical pharmacology of the stereoisomers of leucovorin during repeated oral dosing | 4.0 | 40 | Citations (PDF) |
| 308 | Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer | 4.0 | 31 | Citations (PDF) |
| 309 | The patterns of failure in patients with pathological stage I and II diffuse histiocytic lymphoma treated with radiation therapy alone | 1.5 | 28 | Citations (PDF) |
| 310 | Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: A phase II Illinois Cancer Council study | 2.5 | 11 | Citations (PDF) |
| 311 | Neoadjuvant Vindesine, Etoposide, and Cisplatin for Locally Advanced Non-Small Cell Lung Cancer | 1.0 | 56 | Citations (PDF) |
| 312 | Implantable Venous Access Device: Use in Patients with Advanced Head and Neck Cancer | 2.3 | 9 | Citations (PDF) |
| 313 | Concomitant Hydroxyurea, 5‐Fluorouracil, and Radiation Therapy for Recurrent Head and Neck Cancer: Early Results | 2.3 | 12 | Citations (PDF) |
| 314 | Flow cytometry in hairy cell leukemia before and during interferon alfa-2b therapy | 4.0 | 8 | Citations (PDF) |
| 315 | Hairy-cell leukemia associated with Hodgkin's disease: A case report | 6.5 | 8 | Citations (PDF) |
| 316 | Second malignancies in hairy cell leukemia | 4.0 | 77 | Citations (PDF) |
